Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Healthcare Shares
Mesoblast share price rises after strong quarterly result
Share Market News
Why the Novita Healthcare share price is still on a wild ride
Share Market News
The Next Science share price is tanking on a trading update
Share Market News
Is Paradigm the real deal blockbuster biotech?
Share Gainers
Why Challenger, IOOF, Mesoblast, & Nearmap shares climbed higher today
Share Gainers
Why the Mesoblast share price is charging 8% higher today
Share Market News
Why the Polynovo share price is now up 24x in 5 years
Share Fallers
Why Mesoblast, NAB, Nearmap, & Santos shares crashed lower today
Share Fallers
Why the Mesoblast share price crashed 10% lower today
Share Market News
Mesoblast shares halted as it asks investors to tip in another $75 million
Share Market News
Paradigm reports "ground-breaking" osteoarthritis discovery: Is it the real deal?
Share Market News
Is Paradigm Biopharmaceuticals the share market's next huge winner?
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
